Thus, the results of the present study suggest that CD73/A2AR-targeted therapeutics might be more effective in patients who would benefit less from anti-PD-1/PD-L1 therapy, because CD73 expression by tumor cells appears to serve as a biomarker of responses to therapies targeting the adenosine pathway [21, 29, 32]. This evidence concerns the gene ADORA2A and neoplasm.